Study summary
The FDA approved sparsentan as the first drug specifically for FSGS
What was tested
The FDA's review of sparsentan (Filspari) to reduce proteinuria in FSGS, after a 3-month extension.
What they found
- Approved to reduce proteinuria in adults and children 8 and older with FSGS.
- The decision, first due January 2026, was extended by 3 months to review more data.
What it means
Gives FSGS its first approved targeted treatment; sparsentan was already approved for IgA nephropathy.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.